172 related articles for article (PubMed ID: 21484764)
1. Sclerostin antibody treatment enhances bone strength but does not prevent growth retardation in young mice treated with dexamethasone.
Marenzana M; Greenslade K; Eddleston A; Okoye R; Marshall D; Moore A; Robinson MK
Arthritis Rheum; 2011 Aug; 63(8):2385-95. PubMed ID: 21484764
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of sclerostin by monoclonal antibody enhances bone healing and improves bone density and strength of nonfractured bones.
Ominsky MS; Li C; Li X; Tan HL; Lee E; Barrero M; Asuncion FJ; Dwyer D; Han CY; Vlasseros F; Samadfam R; Jolette J; Smith SY; Stolina M; Lacey DL; Simonet WS; Paszty C; Li G; Ke HZ
J Bone Miner Res; 2011 May; 26(5):1012-21. PubMed ID: 21542004
[TBL] [Abstract][Full Text] [Related]
3. Sclerostin-antibody treatment of glucocorticoid-induced osteoporosis maintained bone mass and strength.
Yao W; Dai W; Jiang L; Lay EY; Zhong Z; Ritchie RO; Li X; Ke H; Lane NE
Osteoporos Int; 2016 Jan; 27(1):283-294. PubMed ID: 26384674
[TBL] [Abstract][Full Text] [Related]
4. Sclerostin antibody increases bone mass by stimulating bone formation and inhibiting bone resorption in a hindlimb-immobilization rat model.
Tian X; Jee WS; Li X; Paszty C; Ke HZ
Bone; 2011 Feb; 48(2):197-201. PubMed ID: 20850580
[TBL] [Abstract][Full Text] [Related]
5. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis.
Li X; Ominsky MS; Warmington KS; Morony S; Gong J; Cao J; Gao Y; Shalhoub V; Tipton B; Haldankar R; Chen Q; Winters A; Boone T; Geng Z; Niu QT; Ke HZ; Kostenuik PJ; Simonet WS; Lacey DL; Paszty C
J Bone Miner Res; 2009 Apr; 24(4):578-88. PubMed ID: 19049336
[TBL] [Abstract][Full Text] [Related]
6. Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength.
Ominsky MS; Vlasseros F; Jolette J; Smith SY; Stouch B; Doellgast G; Gong J; Gao Y; Cao J; Graham K; Tipton B; Cai J; Deshpande R; Zhou L; Hale MD; Lightwood DJ; Henry AJ; Popplewell AG; Moore AR; Robinson MK; Lacey DL; Simonet WS; Paszty C
J Bone Miner Res; 2010 May; 25(5):948-59. PubMed ID: 20200929
[TBL] [Abstract][Full Text] [Related]
7. Sclerostin antibody and interval treadmill training effects in a rodent model of glucocorticoid-induced osteopenia.
Achiou Z; Toumi H; Touvier J; Boudenot A; Uzbekov R; Ominsky MS; Pallu S; Lespessailles E
Bone; 2015 Dec; 81():691-701. PubMed ID: 26409255
[TBL] [Abstract][Full Text] [Related]
8. Rapidly growing Brtl/+ mouse model of osteogenesis imperfecta improves bone mass and strength with sclerostin antibody treatment.
Sinder BP; Salemi JD; Ominsky MS; Caird MS; Marini JC; Kozloff KM
Bone; 2015 Feb; 71():115-23. PubMed ID: 25445450
[TBL] [Abstract][Full Text] [Related]
9. Combination sclerostin antibody and zoledronic acid treatment outperforms either treatment alone in a mouse model of osteogenesis imperfecta.
Little DG; Peacock L; Mikulec K; Kneissel M; Kramer I; Cheng TL; Schindeler A; Munns C
Bone; 2017 Aug; 101():96-103. PubMed ID: 28461254
[TBL] [Abstract][Full Text] [Related]
10. Systemic administration of sclerostin monoclonal antibody accelerates fracture healing in the femoral osteotomy model of young rats.
Feng G; Chang-Qing Z; Yi-Min C; Xiao-Lin L
Int Immunopharmacol; 2015 Jan; 24(1):7-13. PubMed ID: 25479724
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of sclerostin by monoclonal antibody increases bone formation, bone mass, and bone strength in aged male rats.
Li X; Warmington KS; Niu QT; Asuncion FJ; Barrero M; Grisanti M; Dwyer D; Stouch B; Thway TM; Stolina M; Ominsky MS; Kostenuik PJ; Simonet WS; Paszty C; Ke HZ
J Bone Miner Res; 2010 Dec; 25(12):2647-56. PubMed ID: 20641040
[TBL] [Abstract][Full Text] [Related]
12. A short treatment with an antibody to sclerostin can inhibit bone loss in an ongoing model of colitis.
Eddleston A; Marenzana M; Moore AR; Stephens P; Muzylak M; Marshall D; Robinson MK
J Bone Miner Res; 2009 Oct; 24(10):1662-71. PubMed ID: 19419292
[TBL] [Abstract][Full Text] [Related]
13. In vitro dexamethasone pretreatment enhances bone formation of human mesenchymal stem cells in vivo.
Song IH; Caplan AI; Dennis JE
J Orthop Res; 2009 Jul; 27(7):916-21. PubMed ID: 19137580
[TBL] [Abstract][Full Text] [Related]
14. Sclerostin Blockade and Zoledronic Acid Improve Bone Mass and Strength in Male Mice With Exogenous Hyperthyroidism.
Tsourdi E; Lademann F; Ominsky MS; Rijntjes E; Köhrle J; Misof BM; Roschger P; Klaushofer K; Hofbauer LC; Rauner M
Endocrinology; 2017 Nov; 158(11):3765-3777. PubMed ID: 28973221
[TBL] [Abstract][Full Text] [Related]
15. Sclerostin monoclonal antibody enhanced bone fracture healing in an open osteotomy model in rats.
Suen PK; He YX; Chow DH; Huang L; Li C; Ke HZ; Ominsky MS; Qin L
J Orthop Res; 2014 Aug; 32(8):997-1005. PubMed ID: 24782158
[TBL] [Abstract][Full Text] [Related]
16. A new synthetic steroid, osaterone acetate (TZP-4238), increases cortical bone mass and strength by enhancing bone formation in ovariectomized rats.
Fuse H; Fukumoto S; Sone H; Miyata Y; Saito T; Nakayama K; Takahashi H; Matsumoto T; Ogata E
J Bone Miner Res; 1997 Apr; 12(4):590-7. PubMed ID: 9101370
[TBL] [Abstract][Full Text] [Related]
17. Effects of Sclerostin Antibody on the Healing of Femoral Fractures in Ovariectomised Rats.
Liu Y; Rui Y; Cheng TY; Huang S; Xu L; Meng F; Lee WY; Zhang T; Li N; Li C; Ke H; Li G
Calcif Tissue Int; 2016 Mar; 98(3):263-74. PubMed ID: 26603303
[TBL] [Abstract][Full Text] [Related]
18. Sclerostin is expressed in articular cartilage but loss or inhibition does not affect cartilage remodeling during aging or following mechanical injury.
Roudier M; Li X; Niu QT; Pacheco E; Pretorius JK; Graham K; Yoon BR; Gong J; Warmington K; Ke HZ; Black RA; Hulme J; Babij P
Arthritis Rheum; 2013 Mar; 65(3):721-31. PubMed ID: 23233270
[TBL] [Abstract][Full Text] [Related]
19. Adult Brtl/+ mouse model of osteogenesis imperfecta demonstrates anabolic response to sclerostin antibody treatment with increased bone mass and strength.
Sinder BP; White LE; Salemi JD; Ominsky MS; Caird MS; Marini JC; Kozloff KM
Osteoporos Int; 2014 Aug; 25(8):2097-107. PubMed ID: 24803333
[TBL] [Abstract][Full Text] [Related]
20. TNF-alpha antibodies and osteoprotegerin decrease systemic bone loss associated with inflammation through distinct mechanisms in collagen-induced arthritis.
Saidenberg-Kermanac'h N; Corrado A; Lemeiter D; deVernejoul MC; Boissier MC; Cohen-Solal ME
Bone; 2004 Nov; 35(5):1200-7. PubMed ID: 15542046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
